CG Oncology (CGON) director logs 10b5-1 option exercises, sales on Form 4

Rhea-AI Filing Summary

CG Oncology director James Mulay reported option exercises and share sales for CG Oncology, Inc. common stock on January 9, 2026. He exercised a director stock option for 654 shares at an exercise price of $3.72 per share and sold 654 shares of common stock at $44.16 per share. He also exercised a second director stock option for 10,491 shares at an exercise price of $12.59 per share and sold 10,491 shares at $52.99 per share. The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on June 6, 2025, and that the options vest in 36 monthly installments beginning in July 2023 and January 2024, respectively.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulay James

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		M		654	A	$3.72	654	D
Common Stock	01/09/2026		S(1)		654	D	$44.16	0	D
Common Stock	01/09/2026		M		10,491	A	$12.59	10,491	D
Common Stock	01/09/2026		S(1)		10,491	D	$52.99	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$3.72	01/09/2026		M			654	(2)	06/13/2033	Common Stock	654	$0	1,308	D
Director Stock Option (right to buy)	$12.59	01/09/2026		M			10,491	(3)	12/12/2033	Common Stock	10,491	$0	5,240	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

2. The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023.

3. The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.

	/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did CG Oncology (CGON) report on this Form 4?

The Form 4 reports that director James Mulay exercised director stock options and sold the resulting common shares of CG Oncology, Inc. on January 9, 2026.

How many CG Oncology shares did James Mulay sell on January 9, 2026?

He sold 654 shares of common stock at $44.16 per share and 10,491 shares at $52.99 per share, for a total of 11,145 shares sold.

What option exercises did CG Oncology director James Mulay report?

He exercised director stock options for 654 shares at an exercise price of $3.72 per share and 10,491 shares at $12.59 per share, each into CG Oncology common stock.

Were James Mulay’s CG Oncology share sales under a Rule 10b5-1 plan?

Yes. A footnote states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.

How do the CG Oncology director stock options vest for James Mulay?

One stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023, and another vests in 36 substantially equal monthly installments beginning on January 13, 2024.

What is James Mulay’s relationship to CG Oncology?

The filing identifies James Mulay as a director of CG Oncology, Inc. and not a 10% owner or officer.